Acetazolamide in Persons With Type 1 Diabetes - Crossover Trial

Part of paid clinical trials in La Jolla, California.

Sponsor
University of California, San Diego
Study ID
NCT06981234
Phase
PHASE2
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Acetazolamide — DRUG
    Acetazolamide is a potent carbonic anhydrase inhibitor that acts on the renal proximal tubule. Through this mechanism, it inhibits proximal tubule sodium reabsorption.
  • Placebo — DRUG
    Standard pharmaceutical filler will be capsulated and packaged identically to the acetazolamide.

Study Details

The goal of this study is to learn about the effect of the study drug acetazolamide in individuals with Type 1 Diabetes. Specifically, whether acetazolamide provides benefits to the kidneys while minimizing any side effects of the drug. These changes will be measured by laboratory tests that tell us how well the kidneys are functioning.

Key Dates

Start date
Aug 14, 2024
Status verified
Jun 2025
Primary completion
Dec 31, 2026
Completion
Jun 30, 2027

Study Design

Enrollment
25 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment Group A
    250mg Acetazolamide administered twice a day for 10 weeks followed by Placebo Comparator administered twice a day for 10 weeks.
  • Experimental: Treatment Group B
    Placebo Comparator administered twice a day for 10 weeks followed by 250mg Acetazolamide administered twice a day for 10 weeks.

Primary Outcome Measure

Change in mGFR percent [ Time Frame: 10 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UC San Diego Altman Clinical & Translational Research InstituteLa JollaCalifornia92037
Todd May, MS
Charles Ginsberg, MD (PRINCIPAL_INVESTIGATOR)
Joe Ix, MD (SUB_INVESTIGATOR)
Jeremy Pettus, MD (SUB_INVESTIGATOR)

Find similar trials in La Jolla, CA

By condition
By specialty

Related Studies